Acer Therapeutics

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS).  The company was founded in 2013 and is headquartered in Newton, Massachusetts.

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2021 and provided an update on the Company's recent corporate developments.

Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update

NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs). ACER-001 is a nitrogen-binding agent in development for use as adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

The stock price of Acer Therapeutics Inc (NASDAQ: ACER) increased by over 20% pre-market. This is why it happened.

ACER Stock Increases Over 20% Pre-Market: Why It Happened

Cumberland Pharma

Organogenesis Holdings

Xencor

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled

Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the outcome of Acer's pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for ACER-001 for the treatment of Urea Cycle Disorders (UCDs). ACER-001 is a proprietary immediate release multi-particulate powder formulation of sodium phenylbutyrate (NaPB) with a taste-masked coating. ACER-001 is being developed in collaboration with Relief.

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and provided an update on the Company's recent corporate developments.

Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer's management team will present and host one-on-one investor meetings at the upcoming 20th Annual Needham Virtual Healthcare Conference April 12-15, 2021.

Acer Therapeutics to Participate in Needham Virtual Healthcare Conference

NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

Notice of Settlement of Derivative Suits

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and License Agreement for worldwide development and commercialization of ACER-001 for urea cycle disorders (UCDs) and maple syrup urine diseases (MSUD). ACER-001 is a proprietary powder formulation of sodium phenylbutyrate designed to be both taste-masked and immediate release.

Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

The stock price of Acer Therapeutics Inc (NASDAQ: ACER) has increased by over 30% pre-market. This is why it happened.

ACER Stock Price Increases Over 30% Pre-Market: Why It Happened

Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics. The post ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher appeared first on InvestorPlace.

ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher

MGM Resorts

XPeng

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

What's Happening With ACER Stock, MGM Stock, XPEV Stock?

The stock price of Acer Therapeutics Inc (NASDAQ: ACER) has increased by over 100% pre-market as of 6:00 AM ET. This is what you should know about the company.a The post ACER Stock Price Increases Over 100% Pre-Market: What You Should Know About The Company appeared first on Pulse 2.0.

ACER Stock Price Increases Over 100% Pre-Market: What You Should Know About The Company

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on the Company's recent corporate developments.

Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Targeting a pre-NDA meeting with FDA in Q2 2021 Targeting a pre-NDA meeting with FDA in Q2 2021

Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Ur

Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Company's recent corporate developments.

Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

LOS ANGELES--(BUSINESS WIRE)---- $ACER #ACER--ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.

ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at, and participate in, the BIO Investor Forum Digital taking place on October 13-15, 2020. The presentation will be available on-demand during the conference.

News for Acer Therapeutics Stock (ACER)